Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1214

Sort by

Sort Order Select

Journal Articles

Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study

Blood blood.2024025624.

https://doi.org/10.1182/blood.2024025624

Published: 2024

Includes: Supplemental data

Journal Articles

Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis

Seung Kwon Koh, Hyojin Kim, Bohwa Han, Hantae Jo, Junsang Doh, Jeehun Park, Prof, Minh Ha Nguyen, Hyun-Young Kim, Haneul Kim, Seung-Hwan Lee, Chan Hyuk Kim, Duck Cho

Blood blood.2024025673.

https://doi.org/10.1182/blood.2024025673

Published: 2024

Includes: Supplemental data

Journal Articles

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Blood (2024) 144 (Supplement 1): 585.

https://doi.org/10.1182/blood-2024-211449

Published: 2024

Journal Articles

Genetic iron overload aggravates and pharmacological iron restriction improves MDS pathophysiology in a preclinical study

Ada Antypiuk, Steven Vance, Richa Sharma, Sara T. Passos, Michela Asperti, Shobana Navaneethabalakrishnan, Franz Durrenberger, Vania Manolova, Francesca Vinchi, Prof.

Blood blood.2024026135.

https://doi.org/10.1182/blood.2024026135

Published: 2024

Includes: Supplemental data

Journal Articles

Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE

Blood blood.2024024667.

https://doi.org/10.1182/blood.2024024667

Published: 2024

Includes: Supplemental data

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Blood (2023) 142 (Supplement 1): 2235.

https://doi.org/10.1182/blood-2023-184383

Published: 2023

Journal Articles

Measurable Residual Disease Results & Survival with Augmented Early Intensification Therapy in Intermediate-Risk & High-Risk Group Pediatric Acute Lymphoblastic Leukemia Patients Treated with ALL IC-BFM 2009 Protocol: A Single-Center Study from India

Prof. Uttam Kumar Nath, Karthik Kumar, Adamya Gupta, Reshma Benson, DR Arjun Kachhwaha

Blood (2023) 142 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2023-188377

Published: 2023

Journal Articles

Balancing the Bleeding Risk & Treatment Related Complications in Immune Thrombocytopenia - an Unmet Need: Real-World Data from India

Debranjani Chattopadhyay, Anamika Bakliwal, Sudeep Vaniyath, Rituparna Chetia, Gaurav Dhingra, Prof. Uttam Kumar Nath

Blood (2022) 140 (Supplement 1): 11257–11258.

https://doi.org/10.1182/blood-2022-171185

Published: 2022

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137388

Published: 2020

Journal Articles

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134088

Published: 2020

Journal Articles

Systematic Evaluation of Somatic Cis -Regulatory Mutations in Follicular Lymphoma

Firat Uyulur, MSc, Findlay Bewicke-Copley, PhD MSc, BSc, Chinedu Anthony Anene, PhD, Matthias Schlesner, PhD, Icgc MMML-Seq Project, Reiner Siebert, Prof. Dr. MD, Jessica Okosun, MD PhD, Jude Fitzgibbon, PhD, Jun Wang, PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-142623

Published: 2020

Journal Articles

Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial

Kim M Linton, MBChB, PhD, Joanna M Oladipo, PhD, Nicholas Counsell, MSc, Janet Taylor, PhD, Cathy Burton, MBBChir, MA, MD FRCPath, Rachel Oakley, PhD, Joanna Williams, PhD, Sally F Barrington, Prof, MD PhD, Richard Byers, BSc, MSc, MBChB, PhD FRCPath, Timothy Illidge, MDPhD, John A. Radford, MD FMedSci

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136318

Published: 2020

Journal Articles

PTPN11 mutations and Outcomes in Adult Patients with Acute Myeloid Leukemia

Klaus H. Metzeler, MD, Maja Rothenberg-Thurley, PhD, Dennis Görlich, PhD, Maria Cristina Sauerland, Annika Maria Dufour, PhD, Stephanie Schneider, PhD, Marion Subklewe, MD, Jan Braess, MD, Bernhard J. Wörmann, MD, Wolfgang E. Berdel, Prof., MD, Utz Krug, MD, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, MD, Tobias Herold, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137487

Published: 2020

Journal Articles

Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience

Åsa Lindberg, III, Christian Winther Eskelund, Alexandra Albertsson-Lindblad, MD PhD, Arne Kolstad, MD PhD, Anna Laurell, MD PhD, Riikka Räty, MD PhD, Kirsten Grønbæk, Prof,MDDMSc, Christian H. Geisler, MD PhD, Mats Jerkeman, MD PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-133370

Published: 2020

Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase

David Belada, MD PhD, Grzegorz S. Nowakowski, MD, Juan Miguel Bergua Burgues, MD, Marc André, MD, Katerina Kopeckova, MD, Don A. Stevens, MD, Marek Trněný, MD Prof, Ernesto Pérez Persona, Petra Pichler, Pia Klöpfer, Bettina Brackertz, Emanuel Lohrmann, MD, Anirban Lahiry, Neha Shah, Günter Fingerle-Rowson, MDPhD, Wolfram Brugger, John M. Burke, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139788

Published: 2020

Journal Articles

Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting

Annalisa Chiappella, Anna Dodero, Anna Guidetti, Filippo Bagnoli, MD, Vanessa Aragona, Anna Maria Barbui, MD, Stefania Bramanti, MD, Matteo Giovanni Carrabba, MD, Federica Sorà, MD, Pierluigi Zinzani, Prof, MD, Chiara Monfrini, Cristiana Carniti, Paolo Corradini

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-140054

Published: 2020

Journal Articles

The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136544

Published: 2020

Journal Articles

Prevalence of Inherited Predisposition Syndromes in Young Patients with Acute Myeloid Leukemia and Aberrant Karyotype

Martin Kirschner, Benjamin Rolles, MD, Martina Crysandt, Christoph Röllig, Prof., MD, Friedrich Stolzel, MD, Martin Bornhäuser, MD, Carsten Müller-Tidow, MD, Kim Kricheldorf, Margherita Vieri, PhD, Matthias Begemann, Angela Maurer, Jens Panse, MD, Susanne Isfort, Marcin Wlodarski, MD PhD, Sushree Sangita Sahoo, PhD, Tim H Brümmendorf, MD, Edgar Jost, Fabian Beier, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-142815

Published: 2020

Journal Articles

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-138427

Published: 2020

NARROW

Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study

Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Genetic iron overload aggravates and pharmacological iron restriction improves MDS pathophysiology in a preclinical study

Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Measurable Residual Disease Results & Survival with Augmented Early Intensification Therapy in Intermediate-Risk & High-Risk Group Pediatric Acute Lymphoblastic Leukemia Patients Treated with ALL IC-BFM 2009 Protocol: A Single-Center Study from India

Balancing the Bleeding Risk & Treatment Related Complications in Immune Thrombocytopenia - an Unmet Need: Real-World Data from India

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Systematic Evaluation of Somatic Cis -Regulatory Mutations in Follicular Lymphoma

Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial

PTPN11 mutations and Outcomes in Adult Patients with Acute Myeloid Leukemia

Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase

Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting

The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

Prevalence of Inherited Predisposition Syndromes in Young Patients with Acute Myeloid Leukemia and Aberrant Karyotype

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only